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AbstrAct
Mutation of the APC gene occurs in a high percentage of colorectal tumors and 
is a central event driving tumor initiation in the large intestine. The APC protein 
performs multiple tumor suppressor functions including negative regulation of the 
canonical WNT signaling pathway by both cytoplasmic and nuclear mechanisms. 
Published reports that APC interacts with β-catenin in the chromatin fraction to 
repress WNT-activated targets have raised the possibility that chromatin-associated 
APC participates more broadly in mechanisms of transcriptional control. This screening 
study has used chromatin immunoprecipitation and next-generation sequencing to 
identify APC-associated genomic regions in colon cancer cell lines. Initial target 
selection was performed by comparison and statistical analysis of 3,985 genomic 
regions associated with the APC protein to whole transcriptome sequencing data from 
APC-deficient and APC-wild-type colon cancer cells, and two types of murine colon 
adenomas characterized by activated Wnt signaling.
289 transcripts altered in expression following APC loss in human cells were 
linked to APC-associated genomic regions. High-confidence targets additionally 
validated in mouse adenomas included 16 increased and 9 decreased in expression 
following APC loss, indicating that chromatin-associated APC may antagonize 
canonical WNT signaling at both WNT-activated and WNT-repressed targets. Motif 
analysis and comparison to ChIP-seq datasets for other transcription factors identified 
a prevalence of binding sites for the TCF7L2 and AP-1 transcription factors in APC-
associated genomic regions. Our results indicate that canonical WNT signaling 
can collaborate with or antagonize the AP-1 transcription factor to fine-tune the 
expression of shared target genes in the colorectal epithelium. Future therapeutic 
strategies for APC-deficient colorectal cancers might be expanded to include agents 
targeting the AP-1 pathway.
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IntroductIon
Biallelic APC mutations initiate the development 
of a high percentage of colorectal cancers [1, 2]. APC 
encodes a multi-purpose protein whose functions include 
negative regulation of the canonical WNT signaling 
pathway [3]. The APC protein inactivates canonical 
WNT signaling by limiting availability of β-catenin 
[4], a licensing factor that modifies how members of 
the TCF/LEF family of transcription factors regulate 
gene transcription [5]. APC interacts with β-catenin in a 
cytoplasmic complex that facilitates β-catenin degradation 
[6–8], while nuclear APC facilitates both β-catenin 
export to the cytoplasm [9–11] and β-catenin removal 
from specific genomic loci [12]. Interaction of APC with 
chromatin-associated β-catenin negatively regulates the 
expression of MYC, AXIN2, DKK1 and SP5 [12, 13], four 
known WNT targets.
The contribution of APC loss to gene expression 
has been assumed to be exclusively β-catenin-
mediated, although this has not been broadly addressed 
experimentally. This study was designed to identify a more 
comprehensive list of genes transcriptionally regulated 
by chromatin-associated APC and to determine whether 
or not APC mediates their transcriptional repression 
exclusively through displacement of β-catenin from TCF/
LEF family transcription factor complexes.
Chromatin immunoprecipitation of APC and next-
generation sequencing were performed from HCT-116 
colon cancer cells, which express wild-type APC yet can 
model the APC loss observed in the majority of colorectal 
cancers following transient siRNA-based silencing. Gene 
expression data were collected from HCT-116 cells in the 
presence or absence of siRNA targeting APC and were 
compared to ChIP-seq data to identify candidate genes 
controlled by chromatin-associated APC. High-confidence 
candidate genes were likely shared targets of canonical 
WNT signaling and surprisingly included both genes 
increased in expression following APC loss and decreased 
in expression following APC loss.
APC-associated genomic sequences identified in our 
initial screening step exhibited enrichment of validated 
transcription factor binding sites for both TCF7L2 and 
AP-1, and co-occurrence of these transcription factors 
within many of these same genomic regions. These results 
indicate that AP-1 modulation should be investigated as a 
potential therapeutic strategy for targeting the expression 
of a large subset of canonical WNT target genes.
results
APc chIP-seq identified 3,985 APc-associated 
genomic regions
Chromatin immunoprecipitation of APC was 
performed in two biological replicates from HCT-
116 colon cancer cells that express wild-type APC but 
also a degradation-resistant point mutant of β-catenin 
that constitutively activates canonical WNT signaling. 
Previously published reports identified four genes (MYC, 
AXIN2, SP5 and DKK1) regulated by chromatin-associated 
APC [12, 13], and peak-calling thresholds were adjusted 
to pass the stringent false discovery rate (FDR) cutoff of 
1.07% (Figure 1A) while retaining peaks at three out of 
four of these internal positive control loci (Figure 1B). 
ChIP-seq data quality was consistent between replicates 
1 and 2 (Figure 1C). 3,985 genomic regions enriched by 
APC ChIP (p < 0.00001) were identified in both replicates 
relative to their respective inputs (Figure 1D).
rnA-seq data identify 289 APc-responsive 
transcripts encoded by genes located near 
genomic regions enriched by APc chIP-seq
The effects of chromatin-associated APC binding on 
gene transcription were evaluated by RNA-seq analysis 
of HCT-116 cells in the presence or absence of siRNA 
reducing APC expression. Differential expression analysis 
using Cufflinks software [14] identified 1,379 transcripts 
altered in expression following APC silencing (q < 0.05), 
including two out of four positive control transcripts 
(AXIN2 and SP5, Figure 2B). Transcripts were compared 
to 3,985 genomic sequences enriched in both APC 
ChIP-seq replicates, which had been assigned to 2,886 
different genes based on proximity to transcription start 
sites. Comparison of the ChIP-seq and RNA-seq analyses 
identified 125 genes increased and 164 genes decreased 
in expression following APC silencing (Figure 1E). 
This indicates that chromatin-associated APC may act 
as a transcriptional repressor or activator depending on 
the chromatin context, despite the fact that chromatin-
associated APC antagonizes canonical WNT activation of 
all four target genes identified in previous studies [12, 13].
Mouse tumor rnA-seq identifies some APc-
sensitive transcripts as targets of canonical Wnt 
signaling
HCT-116 cells are mismatch repair-deficient and 
relatively unstable. To circumvent these limitations 
and select candidate targets shared with in vivo models 
of tumorigenesis, genes of interest were filtered 
further using colon adenoma RNA-seq data from two 
mouse models of colon tumorigenesis on a C57BL/6J 
background [15]: one expressing wild-type Apc and a 
degradation-resistant mutant β-catenin (as a result of 
treatment with azoxymethane and dextran sulfate sodium 
(AOM/DSS-treated) [16]) and the other with loss of 
function mutations of Apc (ApcMin/+) (Figure 1E). These 
two models of canonical Wnt-driven mouse intestinal 
tumorigenesis were selected for their abilities to generate 
tumors in the colon specifically, resulting in a better basis 
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for comparison to the HCT-116 colon cancer cell model. 
The use of two adenoma types enabled identification of 
shared (canonical Wnt-driven) transcriptional changes 
with higher confidence while filtering out confounding 
factors (such as the inflammatory component of the AOM/
DSS model) [15, 17]. While they differ in that adenomas 
from the ApcMin/+ model lack functional Apc whereas 
those from AOM/DSS-treated mice retain wild-type Apc 
and its chromatin-associated functions, loss of the Apc-
dependent cytoplasmic mechanism promoting β-catenin 
degradation is a common feature of both adenoma types 
that makes them useful for the identification of canonical 
Wnt target genes. Of the 289 candidate transcripts from 
the previous filtering step, 49 changed in expression in the 
same direction as in the human RNA-seq data by at least 
1.5-fold in both ApcMin/+ and AOM/DSS colon adenomas 
relative to non-adenoma colon tissue controls (by one-
sample t-test with a significance cutoff of FDR < 0.1). 
These represent candidate target genes altered by 
canonical WNT signaling. 31 genes increased while 
18 genes decreased in APC/Apc-deficient cells and 
adenomas. An additional filtering criterion focused on 
potential transcriptional regulatory elements identified 
by APC ChIP-seq and located within 10 kb upstream of 
transcription start sites or within first introns. This further 
reduced the number of candidate genes to 16 increased 
and 9 decreased following APC loss (siRNA-based, shown 
in Figure 2A). Ten candidate genes (Figure 2B, 2C) were 
selected for further study based on APC ChIP-qPCR 
validation of enrichment comparable to positive control 
peaks. APC ChIP enrichment of genomic regions in these 
ten loci relative to alpha-satellite repeat negative controls 
Figure 1: Genomic sequences enriched by APc chIP overlap with transcripts altered in expression following APc 
loss. (A) A heat map with rows corresponding to 4-kb genomic regions centered on each peak shared between replicates 1 and 2 shows 
high ChIP signal intensity (red) in each ChIP-seq sample and low background (blue) in each matching input sample. (b) Sequencing data 
visualized using the Integrative Genomic Viewer confirm that three out of four positive control loci (AXIN2, DKK1, MYC and SP5) known 
to be regulated by chromatin-associated APC include genomic regions (red boxes) enriched by APC ChIP. (c) A scatter plot compares 
peak scores (in log scale) from ChIP-seq replicates 1 (x-axis) and 2 (y-axis), indicating high signal:background ratio and consistency in 
peaks scores (Pearson correlation coefficient ρ = 0.8246). (d) Genomic peaks identified in both APC ChIP-seq replicates (p < 0.00001) 
were defined as overlapping if their summits were separated by less than 400-bp (the median of peak width in the peak calling results). (e) 
2,886 genes associated with one or more genomic sequences enriched in both APC ChIP-seq replicates were compared to 448 transcripts 
that increased and 931 transcripts that decreased in the same cell line following APC silencing (q < 0.05). 289 overlapping genes (purple) 
were identified as potential targets of direct transcriptional control by chromatin-associated APC.
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Figure 2: transcription of APc-associated genes changes in APc-deficient cells and mouse adenomas with activated 
Wnt signaling. A list of 2,886 genes associated with genomic regions enriched by APC ChIP were compared with 1,379 transcripts 
altered in expression following APC silencing by siRNA in the same cell line (Panels A, b) and 1,535 transcripts altered in expression 
following both Apc loss and Ctnnb1 activation in mouse colon adenomas (Panel c). Forty-nine genes satisfied both screening criteria, 
including ten candidates depicted in Panels B and C, and two positive controls (AXIN2 and SP5, indicated with red arrows). Two other 
positive controls (also indicated with red arrows) failed to satisfy these screening criteria due to an insignificant change in gene expression 
in either the cell line model alone (MYC) or in both models (DKK1). RNA-seq data for these genes are included in Panels B (human cell 
line) and C (mouse adenomas). Error bars representing standard deviation are included only for conditions for which multiple samples 
were sequenced.
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and comparable to AXIN2 intron 1 and MYC promoter 
element positive controls is clearly visible by qPCR in 
Supplementary Figure 3B (although the overall purpose 
of the figure is different). Expression values for these 
ten targets are depicted from the mouse (Figure 2C) and 
human (Figure 2B) RNA-seq datasets.
binding sites for AP-1 and several promoter-
associated transcription factors were enriched in 
APc peaks
We asked whether chromatin-associated APC is 
recruited to specific genomic sequences exclusively 
through a mechanism mediated by interaction with 
β-catenin [12] or through multiple mechanisms. 
Sequences enriched by APC ChIP were subjected to motif 
analysis using the MatInspector (from the Genomatix 
Software Suite) [18], MEME-ChIP [19] and Regulatory 
Sequence Analysis Tools (RSAT) [20] algorithms 
(Figure 3A). All three algorithms detected enrichment of 
binding sites for the AP-1 transcription factor (variations 
of the TPA response element, TGASTCA), while TCF7L2 
binding sites (expected to predominate based on the 
association of APC with β-catenin and its transcription 
factor-binding partner TCF7L2) were significantly enriched 
according to MEME-ChIP and MatInspector only (Figure 
3A). Enriched motifs identified by multiple algorithms 
(TCF7L2, AP-1, NRF1, SP1, EGR-1 and USF1/2 binding 
sites) were further investigated as candidates to mediate 
APC recruitment and transcriptional control.
the highest-confidence peak subset from APc 
chIP-seq is highly enriched for tcF7l2 and 
AP-1 binding sites.
AP-1 (TGASTCA [21]) and TCF7L2 (WWCAAAG 
[22]) binding motifs occur in 22.6% and 27.0% of all 
peaks, respectively. Those for SP1 (KGGGCGGRRY 
[23], 16.1%), USF1/2 (CACGTG [24], 15.0%), 
NRF1 (GCGCRYGCGC [25], 4.0%) and EGR-1 
(GCGKGGGCG [26], 3.6%) occur less frequently. 
Occurrences of each binding site were then counted within 
a subset of 500 APC-associated genomic sequences with 
the highest p-values for ChIP-seq enrichment (Figure 3A, 
columns 6 and 7). All six candidate transcription factor 
binding motifs show a trend of increasing enrichment as 
lower-confidence peaks are filtered out, with TCF7L2 
(61.8%) and AP-1 (46.8%) binding sites emerging as the 
best represented and most likely to play roles in APC 
recruitment.
APc silencing modifies transcriptional activity 
driven by tcF7l2 motifs.
Luciferase reporter assays were then used to test 
the hypothesis that APC participates in transcription 
factor complexes organized around binding sites 
both for TCF7L2 and for other transcription factors, 
including NRF1, SP1, EGR-1, USF1/USF2 and AP-1. 
Three consecutive repeats of NRF1, SP1, EGR-1 USF1/2 
or AP-1 consensus binding motifs were cloned into the 
pGL3-promoter reporter vector upstream of the firefly 
luciferase gene, similar to positive (TOPFLASH) and 
negative control (FOPFLASH) reporter vectors containing 
six repeats of either wild-type or mutant TCF7L2 (formerly 
known as TCF4) binding sites [3]. APC knockdown 
enhances the ability of the TOPFLASH (TCF7L2) 
positive control to drive luciferase expression by two-
fold, while other transcription factor binding motifs show 
little or no sensitivity to the presence or absence of APC 
(Supplementary Figure 1). These results support a model 
in which TCF7L2 is required for gene activation, without 
excluding the possibility that other transcription factor 
binding motifs mediate transcriptional sensitivity to APC 
in the genomic context of a complete regulatory element.
APc chIP data show significant overlap with 
published ChIP data for β-catenin, TCF7L2, 
AP-1 and sP1
Public ChIP-seq datasets generated from HCT-
116 cells were accessed for β-catenin and TCF7L2, as 
well as for the transcription factors JUND and FOSL1 
(components of heterodimeric AP-1 complexes), USF1, 
SP1 and EGR-1. Data were available from the laboratory 
of Dr. Richard Myers at the HudsonAlpha Institute for 
Biotechnology through the NCBI Gene Expression 
Omnibus [27], and from published work on β-catenin 
from the laboratories of Dr. Shannon McWeeney and 
Dr. Gregory Yochum [22]. Chromosomal locations of 
3,985 APC-associated genomic regions were compared 
to 12,375 TCF7L2 peaks, 2,166 β-catenin peaks, 6,969 
“AP-1” peaks (shared between JUND and FOSL1), 7,754 
SP1 peaks, 3,452 USF1 peaks and 3,396 EGR-1 peaks 
(Figure 3B) to detect overlap. Fold over-representation 
was calculated for the occurrence of transcription factor 
binding site overlap with APC-associated genomic peaks 
relative to expected occurrences by random chance, with 
hypergeometric probability testing to calculate p-values 
(Figure 3C). APC peaks overlapped most significantly 
with TCF7L2 peaks, as well as with SP1, AP-1 and 
β-catenin peaks. USF1 binding sites exhibited more 
modest overlap with APC; overlap with EGR-1 binding 
was not statistically significant (Figure 3C).
overlap of APc chIP-seq with transcription 
factor binding is more pronounced near genes 
associated with increased expression following 
APc loss
Overlap was re-assessed in the subset of APC-
associated genomic regions linked to 257 genes decreased 
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Figure 3: APc-associated genomic sequences are enriched for tcF7l2, AP-1 and sP1 transcription factor binding 
motifs. (A) Motif analysis of all peaks using the MatInspector (Genomatix Software Suite), MEME-ChIP and Regulatory Sequence 
Analysis Tools (RSAT) algorithms detected significant enrichment of predicted binding sites, particularly for the AP-1, EGR-1 and USF1/
USF2 transcription factors. All transcription factor binding motifs occurred more frequently in the subset of 500 genomic sequences 
enriched by APC ChIP with the lowest p-values, particularly those for TCF7L2 (as expected) and AP-1. (b) 3,985 APC ChIP-seq peaks 
were compared with corresponding peaks from several transcription factor ChIP-seq experiments. (c) Overlap data were tabulated to 
calculate fold overrepresentation of each transcription factor binding site among APC-associated genomic regions, relative to expected 
background (p-values calculated by hypergeometric probability test).
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and 292 genes increased in expression following APC 
loss in HCT-116 cells (Figure 4A). TCF7L2 binding 
sites showed the most significant overlap with the APC-
associated regions, while β-catenin-associated sites 
occurred with more dramatic over-representation but 
with less significant p-values due to the smaller dataset 
(Figure 4B). USF1 and EGR-1 binding sites do not occur 
at higher-than-expected rates in these APC-associated 
regions. Surprisingly, both AP-1 and SP1 binding sites 
were overrepresented approximately 2- or 3-fold, and 
occurred more frequently and with greater significance in 
regions associated with increased as opposed to decreased 
expression following APC loss (Figure 4B). These 
observations were consistent with the role of chromatin-
associated APC as a WNT antagonist, as β-catenin and 
TCF7L2 transcriptionally activate most targets while 
repressing transcription of a smaller subset [28–33]. 
tcF7l2 and AP-1 transcription factor binding 
sites frequently occur within the same or 
neighboring genomic regions
Co-occurrence of TCF7L2 and AP-1 binding sites 
was examined in order to test the hypothesis that these 
two transcription factor binding sites might coordinately 
regulate shared target genes. Frequencies were examined 
in a subset of 549 genomic sequences chosen because of 
their enrichment by APC ChIP-seq and their proximity 
to 280 genes altered in expression following APC 
silencing in HCT-116 cells (Supplementary Figure 2). 
Neighboring genomic regions (defined as those assigned 
to the same gene locus based on proximity to the nearest 
transcription start site) were grouped together, making 
the overlap between TCF7L2 and AP-1 binding sites 
much more striking (Supplementary Figure 2). TCF7L2 
Figure 4: TCF7L2, β-catenin, AP-1 and SP1 bind genomic regions associated with increased expression following 
APc loss. (A) Occurrence of validated transcription factor binding sites was examined in 549 genomic sequences enriched by APC 
ChIP-seq and associated with genes increased (292, red circles on right) or decreased (257, red circles on left) in expression following APC 
silencing. (b) Overlap data were tabulated to calculate fold overrepresentation of each transcription factor binding site relative to expected 
background. The hypergeometric probability test indicated higher significance of overlap for all transcription factors with the subset of 
APC-associated genomic regions linked to increased as opposed to decreased expression following APC loss (column 10 compared to 
column 6).
Oncotarget31221www.oncotarget.com
and AP-1 binding sites frequently occur within the same 
genomic regions, particularly in genomic peaks associated 
with genes transcriptionally activated following APC 
silencing (Supplementary Figure 2A vs. 2B). A similar 
co-occurrence was observed between TCF7L2 and SP1 
binding sites (Supplementary Figure 2C vs. 2D). Genomic 
sequences associated with genes transcriptionally 
repressed following APC loss contained fewer binding 
sites for TCF7L2, AP-1 and SP1. These data indicate that 
TCF7L2 and AP-1 or SP1 transcription factors might bind 
neighboring genomic regions and converge on the same 
gene promoter to coordinate transcriptional regulation.
target selection and validation
Ten genomic regions of interest were selected for 
further study (Figure 5) based on differential expression 
of their encoded transcripts following APC loss in both 
cell culture (Figure 2B) and mouse colon adenoma (Figure 
2C) models, and successful APC ChIP-qPCR validation 
comparable to positive control peaks clearly visible by 
qPCR in Supplementary Figure 3B (although the overall 
purpose of the figure is different). APC-associated 
regions from the AXIN2 and MYC loci served as positive 
controls. Analysis of transcription factor ChIP-seq data 
reveals overlap of four candidate regions with TCF7L2 
and three candidate regions with β-catenin binding sites, 
so that canonical WNT signaling is clearly linked to 
ANGPT2 intron 1, the FAT1 enhancer, PHLDB2 intron 1, 
TSPAN5 intron 1, MALL intron 1 and TOM1L2 intron 1. 
AP-1 binding sites overlap with the PHLDB2 intron 1, 
MALL intron 1 and TOM1L2 intron 1 regions, while 
SP1 binding sites overlap with the FAT1 enhancer, 
PHLDB2 intron 1 and MALL intron 1 regions (Figure 5). 
The GPRC5A enhancer contained predicted TCF7L2 
binding motifs not validated by TCF7L2 ChIP (as did the 
MYC promoter, ANGPT2 intron 1, and MALL intron 1, 
Supplementary Figure 4). Five of these loci contain other 
APC-associated ChIP-seq peaks collectively characterized 
by the co-occurrence of TCF7L2 and AP-1 binding sites 
(Supplementary Figure 4, columns 6, 7, and 8). Regions 
from the KDM6B enhancer, MACROD1 promoter and NCL 
intron 1 were of interest due to the absence of TCF7L2 
or β-catenin binding sites. Their inclusion in subsequent 
Figure 5: APc-associated candidate genomic regions contain predicted binding motifs for tcF7l2 and AP-1. 
Transcription factor binding sites identified by ChIP-seq are listed for ten candidate genomic sequences enriched by APC ChIP-seq and 
associated with transcripts altered in expression following APC loss in both in vitro and in vivo models. Since many candidate genes are 
associated with multiple peaks, one peak was chosen in each case based on lowest p-value and shortest distance to transcription start site. 
Most of these genomic sequences contain TCF7L2 and/or AP-1 transcription factor binding sites. Red arrows indicate loci located in AXIN2 
intron 1 and the MYC promoter known to be transcriptionally regulated by chromatin-associated APC.
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experiments tested the hypothesis that chromatin-associated 
APC may modulate the transcription of a subset of genes 
independently of β-catenin or canonical WNT signaling.
silencing of ß-catenin expression reduces 
enrichment of some candidate genomic regions 
by APc chIP
ChIP-qPCR experiments were designed to test 
whether APC requires interaction with β-catenin to 
associate with chromatin at candidate genomic sequences. 
ChIP was performed from HCT-116 cells transfected with 
either scrambled siRNA or siRNA silencing CTNNB1 
(encoding β-catenin). ChIP antibodies targeted either 
β-catenin itself (Supplementary Figure 3A) or APC 
(Supplementary Figure 3B). Reduced enrichment by 
β-catenin ChIP following transfection with anti-CTNNB1 
siRNA (Supplementary Figure 3A) was exhibited by both 
positive controls (from AXIN2 intron 1 and the MYC 
promoter) and six out of ten candidate sequences (from the 
FAT1 enhancer, PHLDB2 intron 1, TSPAN5 intron 1, the 
GPRC5A enhancer, MALL intron 1 and TOM1L2 intron 1). 
Silencing of CTNNB1 produced more subtle effects on 
APC ChIP enrichment of target sequences (Supplementary 
Figure 3B), as only one of the two positive controls (a 
characterized canonical WNT binding site from AXIN2 
intron 1, but not a site from the MYC promoter) and two of 
the candidate genomic sequences (from TSPAN5 intron 1 
and the GPRC5A enhancer) exhibited loss of enrichment. 
Collectively, these knockdown data indicate that TSPAN5, 
GPRC5A, FAT1, PHLDB2, MALL and TOM1L2 are shared 
targets of APC and β-catenin, consistent with the widely 
accepted model that interaction with β-catenin mediates 
APC recruitment to, and function in, the chromatin 
fraction [12, 13, 34]. The remaining three candidates (from 
the KDM6B enhancer, NCL intron 1 and the MACROD1 
promoter) are inconclusive. Six of the seven putative 
targets of APC and β-catenin/canonical WNT signaling 
overlap with TCF7L2 or β-catenin binding sites (Figure 5), 
while the seventh target, the GPRC5A enhancer, has 
a neighboring peak that exhibits TCF7L2 binding 
(Supplementary Figure 4, column 7). Overall, the data 
in Figure 5 and Supplementary Figure 4 indicate that a 
substantial proportion of APC targets are likely β-catenin- 
and TCF7L2-dependent.
candidate genomic regions were screened by 
luciferase reporter assay for APC- or β-catenin-
dependent changes in their ability to drive 
transcription.
Previous studies have constructed a model in 
which APC antagonizes canonical WNT activation of 
target genes [12,  13]. Interestingly, we find that not all 
β-catenin-dependent target genes of chromatin-associated 
APC increase in expression following APC silencing or 
mutation, as GPRC5A, MALL and TOM1L2 decrease 
following APC loss in vitro (Figure 2B) and in vivo (Figure 
2C). These data demonstrate that APC associates with 
chromatin at WNT-repressed target genes as well, likely 
via a similar mechanism of interaction with β-catenin. 
This was further tested using luciferase reporter assays 
to characterize the genomic sequences enriched by APC 
ChIP-seq (Figure 6). Peaks of interest (approximately 
0.5–1.0 kb) were PCR-amplified, cloned into the pGL3-
promoter firefly luciferase vector and transfected into 
HCT-116 cells to measure their ability to drive luciferase 
expression either in the presence or absence of siRNA to 
APC (Figure 6A) or CTNNB1 (Figure 6B). 
Many of the candidate luciferase constructs were 
not sufficient to drive transcription of the reporter above 
baseline levels, including the AXIN2 intron 1 and MYC 
promoter positive controls. Other candidates showed only 
limited responsiveness to siRNA reducing the expression 
of APC. Candidate sequences from PHLDB2 intron 1 and 
MALL intron 1 exhibited high transcriptional activity and 
strong responses to both APC and CTNNB1 silencing. 
APC silencing by siRNA transfection increased luciferase 
activity from the 541-bp PHLDB2 intron 1 construct 
(Figure 6A), while silencing of CTNNB1 (encoding 
β-catenin) decreased luciferase activity (Figure 6B). 
These results indicate that this genomic region contributes 
to the activation of PHLDB2 transcription following APC 
loss both observed both in vitro (Figure 2B) and in vivo 
(Figure 2C). The reporter construct containing a region of 
MALL intron 1 decreased its ability to drive transcription 
following APC silencing (Figure 6A) and increased its 
activity following CTNNB1 silencing (Figure 6B). Both 
observations indicate that this genomic region contributes 
to the transcriptional activation of MALL following APC 
loss (Figure 2B and 2C). It is important to note that this 
effect likely is mediated not only by the loss of APC 
function as a direct regulator of β-catenin in the partially 
chromatinized context of the luciferase construct, but 
also by the up-regulation of β-catenin protein levels that 
typically follows the loss of cytoplasmic APC as a negative 
regulator of β-catenin stability. Expression profiling data 
confirming that Phldb2 increases in expression while Mall 
decreases in expression in mouse adenomas relative to 
adjacent non-adenoma tissue (Figure 2C) match reports 
that canonical WNT signaling activates the transcription 
of certain genes and simultaneously represses the 
transcription of others [28–33]. Collectively, the results 
of this study indicate that chromatin-associated APC may 
function to reverse the effects of canonical WNT signaling 
on both activation and repression of targets (Figure 7).
dIscussIon
This study has identified high-confidence APC 
targets genes by comparing mechanistic (ChIP-seq) 
and functional (RNA-seq) data, similar to other studies 
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identifying WNT-activated target genes [35, 36]. The 
present study adds evidence that canonical WNT signaling 
represses distinct target genes in human colorectal cancers 
and that APC antagonizes WNT repression at these loci. 
This pattern differs from the better-characterized canonical 
WNT targets but matches a smaller group of targets found 
in model systems such as Drosophila [28, 29], chick [30], 
mouse [31, 32] and human melanocytes [33].
The mechanism by which this occurs remains 
unclear. Published studies of chromatin-associated APC 
have established its ability to antagonize canonical WNT 
transactivation of targets, and have shown that interaction 
with β-catenin and recruitment of co-repressors such as CtBP-
1, TLE-1 and HDAC1 are key elements of that mechanism 
[12, 13, 34]. APC and CtBP-1 interact with these loci 
transiently, and their disappearance coincides with the loss of 
Figure 6: APC or CTNNB1 silencing alters transcriptional activity from elements in the PHLDB2 and MALL loci. 
Ten genomic sequences associated with APC and two positive control sequences (from AXIN2 intron 1 and MYC promoter, indicated by 
red arrows) were PCR-amplified, cloned into the pGL3-promoter firefly luciferase vector and transfected into HCT-116 cells previously 
transfected with either scrambled siRNA (purple) or siRNA targeting APC (red, panel A) or CTNNB1 (blue, panel b). The PHLDB2 intron 
1 construct was more active following APC silencing (panel A) and less active following CTNNB1 silencing (panel B), similar to the 
pTOPFLASH positive control. The MALL intron 1 construct was less active following APC silencing and more active following CTNNB1 
silencing. Errors bars are based on standard deviation, and FDR values lower than 0.05 are indicated (1-tailed Student’s t-test).
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β-catenin and the appearance of the more stable co-repressors 
[12]. Our findings indicate that the antagonistic relationship 
between chromatin-associated APC and β-catenin exists at 
WNT-repressed genes such as MALL as well. We hypothesize 
that regardless of whether canonical WNT signaling activates 
or represses transcription of a particular gene, APC exerts 
an antagonistic effect by mediating β-catenin removal 
(Figure 7). Further mechanistic experiments will be 
necessary to test this hypothesis and to identify co-activators 
involved in APC regulation of genes such as MALL.
Among the candidate genes identified in this 
study are seven characterized β-catenin-dependent 
Figure 7: Models of WNT-mediated transcriptional activation and repression involving TCF7L2, AP-1, β-catenin and 
APc. Our data suggest at least two models in which canonical WNT-mediated transcriptional activity, APC and AP-1 alter gene expression. 
(A) Activation of canonical WNT signaling up-regulates transcription of PHLDB2 through a previously-characterized mechanism in which 
β-catenin binds to the TCF7L2 transcription factor, promoting DNA bending that brings transcriptional machinery (including AP-1) into 
closer association with the proximal promoter. APC disrupts this association by mediating the removal of β-catenin from the complex. 
(b) Activation of canonical WNT signaling may down-regulate AP-1-dependent transcription of MALL through a mechanism in which 
β-catenin binding to TCF7L2 disrupts interaction of transcriptional machinery with the proximal promoter. APC may relieve this disruption 
by removing β-catenin from the complex.
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targets of chromatin-associated APC. The ANGPT2, 
FAT1, PHLDB2 and TSPAN5 transcripts increase while 
GPRC5A, MALL and TOM1L2 decrease following APC 
loss in vitro or in vivo. An intronic regulatory element 
from the PHLDB2 locus is transcriptionally activated 
by β-catenin/TCF7L2 and repressed by APC, while 
an intronic regulatory element from the MALL locus is 
transcriptionally repressed by β-catenin/TCF7L2 and 
activated by APC. It is important to note that the effects 
of APC on their transcription are likely mediated by both 
cytoplasmic and nuclear functions of the APC protein that 
cannot be distinguished in our reporter assays. Previously 
published studies of the relationship between chromatin-
associated APC and canonical WNT signaling indicate 
an antagonistic relationship that is consistent with the 
functions of APC in facilitating nuclear export and 
cytoplasmic degradation of β-catenin. The co-existence of 
these three seemingly redundant mechanisms emphasizes 
the critical importance of APC as a switch whose 
activation in maturing cells of the colorectal epithelium 
triggers rapid and tight negative regulation over the 
nuclear functions of β-catenin at multiple levels.
The chromatin-associated fraction of the APC 
tumor suppressor protein associates with a large number 
and variety of genomic regions, with patterns in genomic 
distribution and transcription factor binding site content 
that match ChIP-seq studies of other known components 
of the canonical WNT signaling pathway [22, 35]. 
Binding sites for the TCF7L2 transcription factor are 
enriched among APC-associated regions (Figures 3, 
4), similar to published ChIP-seq results for β-catenin 
[22], a known co-regulator of TCF7L2 transcription 
factor complexes. These similarities are consistent with 
the reported co-localization of both proteins to target 
sites in the chromatin fraction and the interpretation 
that APC can be recruited to chromatin by β-catenin 
binding [12]. Despite similarities to related studies, it is 
important to note the limitations of informatics analyses 
that are two-dimensional and assign ChIP-seq peaks 
to RNA-seq hits based on the assumption that each 
APC-bound region controls gene expression from the 
nearest transcription start site, where the more realistic 
spatial organization of chromatin in three dimensions 
enables regulatory relationships that are not as long-
range as they appear in two-dimensional units (bp). It 
is particularly important to consider these limitations in 
light of the heterogeneous effects of APC on “control” 
loci such as SP5, which lacks obvious APC-associated 
sites according to ChIP-seq, but nevertheless shows 
sensitivity to APC loss in the RNA-seq data. Three-
dimensional analyses based on chromatin conformation 
capture (3C) methodologies are required for a more 
comprehensive identification of the genes targeted by 
APC-associated regions genome-wide.
Mounting evidence links β-catenin [22, 37, 38] 
and now APC to genomic regions containing predicted 
AP-1 binding sites. Canonical WNT signaling shares 
transcriptional targets with the AP-1 signaling pathway [37, 
38], and previous ChIP-seq targeting β-catenin [22] similarly 
found AP-1 binding motif enrichment. The AP-1 component 
c-JUN physically interacts with TCF7L2 in HCT-116 cells, 
co-regulating the JUN promoter in a β-catenin-dependent 
manner [37]. AP-1 components co-immunprecipitate with 
β-catenin and co-regulate expression of the TCF7L2 target 
genes MYC and CCND1 [38]. Co-occurrence of predicted 
TCF7L2 and AP-1 binding sites in many of the same or 
neighboring genomic regions (Supplementary Figure 2) 
indicates that the two transcription factors may coordinately 
regulate the transcription of shared target genes in the 
colorectal epithelium. SP1 transcription factor binding sites 
are similarly over-represented among APC ChIP-seq peaks 
(Figures 3, 4) and co-occur with TCF7L2 binding sites 
(Supplementary Figure 2).
It is as yet unclear what determines whether 
canonical WNT signaling activates or represses a 
particular target gene in human cells. Some correlation 
exists between the presence of TCF7L2 and AP-1 
transcription factor binding sites and canonical WNT 
activation of transcription, as both types of binding site 
are more prevalent within the subset of genomic sequences 
associated with transcripts increased in expression 
following APC loss (Supplementary Figure 2A vs. 2B). 
However, all seven loci characterized in this study include 
APC-associated genomic regions that contain both 
TCF7L2 and AP-1 binding motifs, regardless of whether 
they are transcriptionally increased (ANGPT2, FAT1, 
PHLDB2 and TSPAN5) or decreased (GPRC5A, MALL 
and TOM1L2) following APC silencing.
β-catenin/TCF7L2 may control transcription by 
modulating AP-1 binding or subsequent AP-1-dependent 
steps. If canonical WNT signaling exerts transcriptional 
effects largely by modifying AP-1 activity on shared 
target genes, WNT-activated targets may be those in 
which TCF7L2 promotes AP-1 binding or coordinates 
long-distance interactions between AP-1 proteins from 
multiple binding sites at the same promoter (Figure 7A). 
This would be consistent with the observation that many 
target genes (including PHLDB2) have multiple associated 
peaks, some with either TCF7L2 or AP-1 binding sites, 
and some with both. These regulatory elements likely 
interact with one another and converge on the promoter to 
co-regulate transcription. According to this model, WNT-
repressed targets (Figure 7B) might be those in which 
TCF7L2 instead competes with AP-1 binding to adjacent 
sites or interferes with long-distance interactions between 
AP-1 proteins and their intended target promoters.
The MALL gene was confirmed (Figure 6) as a 
direct APC target repressed by canonical WNT signaling. 
These data imply that other targets with similar expression 
patterns may be similarly regulated candidates. Their value 
as potential markers for prognosis or as therapeutic targets 
may be important. MALL is down-regulated in colorectal 
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cancers [39], with this low expression predicting tumor 
recurrence, metastasis and poor outcome [40]. MALL 
is a member of the glycolipid-enriched membrane raft 
family [41] and interacts with caveolin-1 [42], potentially 
linking it to integrin signaling and cell migration [43]. 
High expression of PHLDB2 in colorectal cancer is also 
associated with shorter metastasis-free survival. PHLDB2 
is required for cell migration and invasion of the HCT-116 
colon cancer cell line [44]. It is regulated by PI3K [45] and 
contributes to microtubule stabilization [46], and helps 
promote cell protrusions by linking actin and adhesion 
dynamics [47]. MALL, PHLDB2 and other genes responsive 
to APC are consistent with the emerging role of canonical 
WNT signaling targets in colorectal cancer invasion and 
progression [48–50], in addition to the better-characterized 
role of the pathway in colorectal tumor initiation.
Finally, this study strongly suggests that targets of 
the canonical WNT signaling pathway should be stratified 
into several categories, based on criteria such as the 
direction of their transcriptional response to activation of 
the pathway. The high rates of co-occurrence of TCF7L2 
and AP-1 binding sites observed in the ChIP-seq data 
further indicate that the presence or absence of AP-1 
binding sites may be an additional criterion by which 
to sort target genes. Interestingly, the AP-1 component 
c-Jun is required for the full phenotype of Apc loss in 
mice, as introduction of Jun mutations into the ApcMin/+ 
mouse model lead to lower polyp number, reduced polyp 
size and longer life span [37]. Canonical WNT signaling 
promotes the maintenance of progenitor cell phenotypes 
in the stem cell compartment of the colorectal epithelium, 
and may do so in part by fine-tuning the transcription of 
target genes shared with AP-1. Modulation of the AP-1 
pathway is increasingly feasible with the emergence of the 
small molecule T-5224, designed to inhibit transactivation 
by blocking DNA binding by the leucine zipper domain 
of c-FOS [51, 52]. T-5224 can be one interventional 
strategy for WNT-driven colorectal tumors and has been 
characterized as an agent for the treatment of inflammatory 
conditions such as rheumatoid arthritis [52] and injuries of 
the kidneys [53] and liver [54] as well as oral cancer [55]. 
The natural product veratramine is an additional small 
molecule inhibitor of AP-1 that inhibits transactivation by 
interacting not with AP-1 itself but with its TGACTCA 
binding motifs [56]. These agents may show potential as 
therapeutic interventions to reduce the contribution of 
shared TCF7L2/AP-1 target genes to colorectal tumor 
progression.
MAterIAls And Methods
chromatin immunoprecipitation and next-
generation sequencing
APC ChIP was performed from 60–70% confluent 
HCT-116 cells in a 150-mm dish. Cells were maintained 
in McCoy’s 5A medium including glutamine and 
supplemented with 10% FBS. Following formaldehyde 
crosslinking, nuclei were isolated and resuspended in 1 mL 
of Lysis Buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 
5 mM EDTA, 0.1% SDS, 1% Triton X-100, 0.5% Sodium 
Deoxycholate, 1 mM PMSF with mammalian protease 
inhibitor cocktail). Probe-based sonication was performed 
at 4° C over a period of 40 minutes total by 30 pulses of 
10-seconds each at 35% amplitude. Average fragment size 
was further reduced to ~1kb using micrococcal nuclease 
(Affymetrix, Inc.). Input material was pre-cleared by 
2-hour incubation with 5 μg rabbit IgG antibody and 40 
μL of pre-equilibrated Protein G Dynabead slurry (Thermo 
Fisher Scientific) at 4° C with rotation. 100 μL of the 
resulting supernatant was saved as “pre-cleared input”, and 
the remainder was used for α-APC ChIP in combination 
with 10 μg of α-APC antibody (a polyclonal antibody 
recognizing the C-terminal 50 amino acids of APC, 
catalog #A3081A, Bethyl Laboratories, Inc.). ChIP was 
performed according to an established protocol [57], with 
the following exceptions. 40 μL of pre-equilibrated Protein 
G Dynabead slurry (Thermo Fisher Scientific) was used to 
pull down antibody-APC complexes, and each of the wash 
steps was performed twice. Yields from multiple parallel 
α-APC ChIP reactions were pooled to obtain the 10 ng 
required for ChIP-seq library preparation, and the PCR 
Purification Kit (QIAGEN) was used to clean up reactions 
prior to library preparation. Two separate biological 
replicates were performed under identical conditions 
several months apart, from HCT-116 cells at passage 
numbers between 10 and 20 since they were purchased 
from the American Type Culture Collection. Library 
preparation was performed using the NEBNext ChIP-Seq 
Library Prep Master Mix Set for Illumina, using adaptors 
AD005 and AD019 (New England Biolabs) for input and 
ChIP libraries, respectively. Size selection was performed 
by E-gel (Life Technologies, Inc.) to obtain fragments of 
300-400-bp in size. Next-generation sequencing (50-bp, 
single-end) was performed by the OSU Genomics Shared 
Resource using a HiSeq 2500 instrument (Illumina, Inc.).
chIP-seq data analysis
97–98% of reads for two ChIP-seq samples and the 
matching input samples passed quality control filters, and 
the Burrows-Wheeler Aligner generated bam alignment 
files using UCSC hg19. The Model-based Analysis of 
ChIP-Seq version 2 (MACS2) tool [58] performed peak-
calling and generated peak scores, p-values and false 
discovery rates (FDR) for each peak. Peak score threshold 
was adjusted to lower the noise observed in input files 
while retaining internal positive control peaks in the 
AXIN2, DKK1 and MYC loci. The RefGene database 
was used to annotate peak regions, determine distances 
to transcription start sites and assign peaks to genes. The 
distribution of peak locations relative to transcription start 
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sites is shown in Supplementary Figure 5. R software 
identified overlapping peaks present in both replicates 
with summits separated by less than 400-bp (the median of 
peak width in the peak calling results). ChIP-seq datasets 
are available through NCBI’s Gene Expression Omnibus 
(accession #GSE99264, https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE99264). Reviewers must use 
the secure token uzojsoqgddktvev. MEME-ChIP [19], 
Regulatory Sequence Analysis Tools (RSAT) [20], and 
MatInspector [18] algorithms were used with standard/
default settings to perform initial analyses of all ChIP-seq 
peak sequences from FASTA files.
Whole transcriptome profiling of hct-116 cells
HCT-116 cells were transfected on consecutive 
days with pooled siRNA (Dharmacon) targeting APC (L-
003869-00-0005), scrambled sequence (D-001810-10-05), 
or neither (mock transfection). Cells were harvested 
48 hours later by standard Trizol (Life Technologies 
catalog # 15596-026) isolation protocol. Single-read 
library preparation was performed using the TruSeq RNA 
Library Preparation Kit (Illumina catalog # RS-122-
2001). Next-generation sequencing was performed by 
the OSU Genomics Shared Resource using an Illumina 
Genome Analyzer II instrument. The Cufflinks software 
program [14] assigned reads to transcripts, performed 
quantification and calculated statistical significance. The 
Cuffdiff program provided transcript levels (as FPKM) 
and (FDR-adjusted) q-values based on fold-changes 
and sample sizes and identified significantly significant 
differences between anti-APC siRNA and scrambled 
siRNA-transfected conditions (q < 0.05). RNA-seq datasets 
are available through the NCBI Gene Expression Omnibus 
(accession #GSE99264).
Whole transcriptome profiling of ApcMin/+ and 
AoM/dss mouse colon tumors
RNA isolation, preparation of sequencing libraries 
and processing of these data were described previously 
[15]. The presence of activating mutations in Ctnnb1 
was confirmed by Sanger sequencing of cDNA from the 
adenomas from AOM/DSS-treated mice (Supplementary 
Figure 6). Transcripts of interest were identified based on 
1.5-fold-changes in expression in adenomas from both 
ApcMin/+ and AOM/DSS-treated mice relative to their 
respective non-adenoma colon tissue controls (using one-
sample t-test with a significance cutoff of FDR < 0.05) 
in the same direction as was observed in human cells 
following APC silencing. For multiple test correction, fold-
changes in expression for individual genes were ordered by 
p-value and ranked, and FDR was calculated by multiplying 
p-values by the total number of tests and dividing by their 
rank (Benjamini and Hochberg method). RNA-seq datasets 
are available through NCBI’s Gene Expression Omnibus 
(accession #GSE98496, https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token=wpidaoiuphunvcn&acc=GSE98496).
APc chIP-seq overlap with publicly available 
transcription factor chIP-seq datasets
Public ChIP-seq datasets were obtained through 
accession numbers GSM1010846 (EGR-1) GSM1010756 
(FOSL1), GSM1010847 (JUND), GSM803474 
(POLR2A), GSM1010902 (SP1), GSM782123 (TCF7L2), 
and GSM1010836 (USF1). The coordinates of β-catenin 
ChIP-seq peaks were obtained from published work 
from the laboratories of Dr. Shannon McWeeney and 
Dr. Gregory Yochum [22]. All datasets included lists of 
peaks from two ChIP-seq replicates (except for β-catenin); 
peaks for each transcription factor were narrowed down to 
only those shared between both replicates. Chromosomal 
locations of 3,985 APC-associated genomic regions were 
compared to 12,375 TCF7L2 peaks, 2,166 β-catenin 
peaks, 6,969 “AP-1” peaks (shared between both JUND 
and both FOSL1 replicates), 7,754 SP1 peaks, 3,452 USF1 
peaks and 3,396 EGR-1 peaks. Overlap between an APC 
peak and a transcription factor peak was scored only when 
the centers of two corresponding peaks were no more than 
400-bp apart.
luciferase reporter assays
Genomic regions were PCR amplified, restriction 
digested and ligated into the pGL3-promoter vector 
upstream of the firefly luciferase gene. Restriction 
enzymes pairs varied depending on the target, with Kpn 
I and Bgl II used for the majority. Primer sets are listed 
in Supplementary Figure 7. HCT-116 cells were seeded 
in 6-well plates and transfected on consecutive days with 
pooled siRNA (Dharmacon) targeting APC (L-003869-00-
0005), targeting CTNNB1 (encoding β-catenin, L-003482-
00-0010), or with scrambled sequence (D-001810-10-05) 
using Dharmafect 2 reagent (T-2002-01). 12 hours later, 
cells were trypsinized and re-seeded into 96-well plates 
at a density of 25,000 cells per well. Cells were co-
transfected 12-hours post-plating with a firefly luciferase 
construct (9 ng per well) and a Renilla luciferase construct 
(1 ng per well). Luciferase assays were performed 24 
hours later using the Promega Dual-Luciferase Reporter 
Assay System (catalog #E1910). The ratio of firefly 
luciferase to Renilla luciferase signal for each well was 
normalized to the average across all wells transfected 
with empty vector. Three independent experiments were 
performed and two-tailed Student’s t-test was used to 
calculate p-values to test the hypothesis that each construct 
was APC-sensitive or β-catenin-sensitive, relative to its 
scrambled siRNA control. For multiple test correction, 
fold-changes in expression for individual constructs were 
ordered by p-value and ranked, and FDR was calculated 
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by multiplying p-values by the total number of tests and 
dividing by their rank (Benjamini and Hochberg method).
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